Stock Research: GSK

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

GSK

LSE:GSK GB0009252882
39
  • Value
    82
  • Growth
    62
  • Safety
    Safety
    12
  • Combined
    51
  • Sentiment
    42
  • 360° View
    360° View
    39
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

GSK plc is a global biopharma company focused on developing medicines and vaccines. It operates in the pharmaceuticals industry, with a focus on respiratory, immunology, oncology, HIV, and infectious diseases. GSK's operations are global. In the last fiscal year, the company had a market cap of $76,670 million, profits of $28,223 million, and revenue of $39,254 million, with 68629 employees.

more

ANALYSIS: With an Obermatt 360° View of 39 (better than 39% compared with alternatives), overall professional sentiment and financial characteristics for the stock GSK are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for GSK. The consolidated Value Rank has an attractive rank of 82, which means that the share price of GSK is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 82% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 62, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of 42. Professional investors are more confident in 58% other stocks. Worryingly, the company has risky financing, with a Safety rank of 12. This means 88% of comparable companies have a safer financing structure than GSK. ...read more

more
Index
FTSE All Shares
FTSE 100
FTSE 350
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 3-Nov-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
82 88 89 86
Growth
62 16 55 21
Safety
Safety
12 20 8 1
Sentiment
42 69 70 16
360° View
360° View
39 54 63 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
12 13 19 33
Opinions Change
41 81 71 16
Pro Holdings
n/a 87 80 78
Market Pulse
34 52 65 25
Sentiment
42 69 70 16
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
82 88 89 86
Growth
62 16 55 21
Safety Safety
12 20 8 1
Combined
51 38 46 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
76 50 67 85
Price vs. Earnings (P/E)
63 91 89 87
Price vs. Book (P/B)
57 20 26 34
Dividend Yield
90 96 96 92
Value
82 88 89 86
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
44 42 39 37
Profit Growth
91 38 58 23
Capital Growth
55 17 64 6
Stock Returns
49 32 52 78
Growth
62 16 55 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
13 13 6 7
Refinancing
6 11 9 1
Liquidity
64 71 45 41
Safety Safety
12 20 8 1

Similar Stocks

Discover high‑ranked alternatives to GSK and broaden your portfolio horizons.

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Genus

LSE:GNS
Country: United Kingdom
Industry: Biotechnology
Size: Medium
Full Stock Analysis

Jupiter

LSE:JUP
Country: United Kingdom
Industry: Asset Management & Custody
Size: Medium
Full Stock Analysis

AEP Plantations

LSE:AEP
Country: United Kingdom
Industry: Agricultural Products
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a mixed bag with good value and high growth balanced by risky financing and negative sentiment. This is a risky stock that requires conviction; you should only consider it if you are willing to conduct further research into the underlying sentiment and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: